Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (3)	9/28/1999 10:45:00 AM
From: Edscharp	Respond to of 75

Opal, Good idea for a thread. I came to the conclusion about a year ago not to invest in early biotech startups. With the ocassional exception, I now confine my biotech investments to companies that have at least one P3 clinical trial for a large target group and preferably have several ongoing P2 trials in the works. ISIP and IMCL are on the list and, unfortunately, XOMA.

To: opalapril who wrote (3)	9/28/1999 10:45:00 AM
From: Arthur Radley	Respond to of 75

Opa, Good idea for a thread....just wish you hadn't brought up XOMA in the first post to remind me of this biotech/publishing house debacle of a company that I've invested in for way toooo many years. To offer several stocks that I think are on the threshold of MAKING it, I offer TTP (and after investing in XOMA I might need their schizophrenia drug) and CLGY. Since XOMA has been a pain in the .ss, CLGY has the answer to that problem. TTP is in PHASE III testing and the good thing is that NOVARTIS is footing the bill for ZOMARIL. If anyone listened to NOVARTIS presentation last week in NYC, they will know that they spent considerable time talking about the TTP/ZOMARIL product. As for CLGY, they have just concluded their PHASE III trial and news should be released in short order for their anal fissure product. Those are my offerings and I would suggest everyone do some DD on each of these companies. Good luck!